Submit Covaxin Phase 3 efficacy data before seeking nod for kids trials: SEC, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

The Subject Expert Committee (SEC), which advises the Indian drug regulator Drugs Controller General of India (DCGI), has asked Bharat Biotech to submit efficacy and safety data from its ongoing Phase III Covaxin trials before seeking approval for conducting trials on children., The Subject Expert Committee (SEC), which advises the Indian drug regulator Drugs Controller General of India (DCGI), has asked Bharat Biotech to submit efficacy and safety data from its ongoing Phase III Covaxin trials before seeking approval for conducting trials on children., , Read More